Join
Live feed
·
PRReleasevia Quantisnow
Arcus Biosciences Inc. logo

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
RCUS· Arcus Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RCUS (Arcus Biosciences Inc.) and more on Quantisnow.